0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Axcella Health Inc

Healthcare US AXLA

NoneUSD
-(-%)

Last update at 2024-01-29T12:44:55.885672Z

Day Range

--
LowHigh

52 Week Range

0.3841.25
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -81.18600M -64.62800M -56.52700M -59.03700M -36.06900M
Minority interest - - - - 0.00000M
Net income -82.36300M -67.11800M -58.80900M -59.97300M -36.06900M
Selling general administrative 15.81M 18.71M 16.80M 15.78M 8.41M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.41M 0.29M 0.42M 0.66M 1.07M
Ebit -76.98800M -62.13400M -54.25500M -57.43900M -33.88200M
Ebitda -67.00900M -61.84600M -53.83600M -57.38800M -32.81100M
Depreciation and amortization 9.98M 0.29M 0.42M 0.05M 1.07M
Non operating income net other - - 0.32M - -
Operating income -76.98800M -61.84600M -53.83600M -57.43900M -33.89600M
Other operating expenses 72.80M 61.85M 53.84M 57.44M 33.90M
Interest expense 3.02M 2.92M 3.01M 3.40M 0.00000M
Tax provision - - - - -
Interest income 0.50M 0.14M 0.31M 1.81M 2.24M
Net interest income -2.51700M -2.77800M -2.70100M -1.58100M -2.15900M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 1.18M 2.49M 2.28M 0.94M -2.17300M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 72.80M 61.85M 53.84M 57.44M 33.90M
Cost of revenue - - - - 0.00000M
Total other income expense net -4.19800M -2.78200M -2.69100M -1.59800M -0.01400M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -81.18600M -64.62800M -56.52700M -59.03700M -36.06900M
Net income applicable to common shares - -64.62800M -56.52700M -59.08300M -36.22200M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 18.93M 57.73M 109.59M 94.36M 81.84M
Intangible assets - - - - 0.00000M
Earning assets - - - - -
Other current assets 0.88M 1.60M 1.69M 1.49M 0.83M
Total liab 14.76M 35.72M 34.21M 34.13M 33.33M
Total stockholder equity 4.16M 22.01M 75.38M 60.22M 48.51M
Deferred long term liab - - - - 0.25M
Other current liab 7.85M 5.85M 5.49M 6.36M 5.30M
Common stock 0.07M 0.04M 0.04M 0.02M 0.02M
Capital stock 0.07M 0.04M 0.04M 0.02M 0.02M
Retained earnings -418.42700M -337.24100M -272.61300M -216.08600M -157.04900M
Other liab - 0.50M 1.21M 0.88M 1.90M
Good will - - - - 0.00000M
Other assets - 0.21M 0.21M 0.21M 0.47M
Cash 17.15M 23.57M 71.59M 92.05M 79.47M
Cash and equivalents - - - - -
Total current liabilities 14.15M 10.15M 7.78M 8.36M 6.91M
Current deferred revenue - - - - -
Net debt -14.98600M 1.50M -46.36800M -67.15600M -54.94500M
Short term debt 1.59M - - - 0.00000M
Short long term debt - - - - 0.00000M
Short long term debt total 2.16M 25.07M 25.22M 24.90M 24.52M
Other stockholder equity 422.52M 359.26M 347.99M 276.29M 208.94M
Property plant equipment 0.69M 0.87M 0.36M 0.61M 1.08M
Total current assets 17.15M 55.05M 107.33M 92.05M 80.30M
Long term investments - - - - 0.00000M
Net tangible assets - 22.01M 75.38M 60.22M -149.75300M
Short term investments 0.00000M 31.47M 35.74M - 0.00000M
Net receivables - - - - -
Long term debt - 25.07M 25.22M 24.90M 24.52M
Inventory - - - - 0.00000M
Accounts payable 4.71M 4.30M 2.29M 2.00M 1.61M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income - -0.05200M -0.03400M -94.35900M -3.39300M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - 0.04M 0.02M 0.02M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - -272.61300M - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - -
Non currrent assets other 1.09M 1.81M 1.90M 1.70M 0.47M
Deferred long term asset charges - - - - -
Non current assets total 1.78M 2.68M 2.26M 2.31M 1.54M
Capital lease obligations 2.16M - - - -
Long term debt total - - 25.22M 24.90M 24.95M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 30.92M 3.05M -35.92000M -35.92000M -0.58600M
Change to liabilities 0.00000M 2.05M 0.31M 0.37M 0.59M
Total cashflows from investing activities 30.92M 3.05M -36.11900M -0.11700M -0.58600M
Net borrowings - -0.13100M -0.03900M -0.13100M 6.00M
Total cash from financing activities 32.24M 3.16M 65.43M 63.67M 63.95M
Change to operating activities 2.78M 0.29M -0.96900M 0.63M 0.41M
Net income -81.18600M -64.62800M -56.52700M -59.03700M -36.06900M
Change in cash -6.42700M -48.01600M -20.46300M 12.59M 32.65M
Begin period cash flow 23.57M 71.59M 92.05M 79.47M 46.82M
End period cash flow 17.15M 23.57M 71.59M 92.05M 79.47M
Total cash from operating activities -69.58800M -54.22100M -49.77100M -50.96200M -30.71200M
Issuance of capital stock 53.49M 4.78M 65.32M 64.55M 58.86M
Depreciation 0.41M 0.29M 0.42M 0.66M 1.07M
Other cashflows from investing activities - - 0.04M 0.02M 0.07M
Dividends paid - - - - 0.00000M
Change to inventory - - - - 0.00000M
Change to account receivables - - - - 0.00000M
Sale purchase of stock - - 65.47M 64.89M 58.91M
Other cashflows from financing activities 4.92M -1.49000M 0.10M -0.88000M 63.95M
Change to netincome - 7.78M 7.00M 6.41M 3.29M
Capital expenditures 0.43M 0.28M 0.24M 0.14M 0.66M
Change receivables - - - - -
Cash flows other operating - - -0.96900M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -20.46300M - -
Change in working capital 3.16M 2.34M -0.65800M 1.00M 1.00M
Stock based compensation 3.58M 6.24M 6.29M 5.82M 2.78M
Other non cash items 4.44M 1.53M 0.71M 0.56M 0.53M
Free cash flow -70.01400M -54.49600M -50.01000M -51.09800M -31.37100M

Fundamentals

  • Previous Close -
  • Market Cap1.64M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-41.30200M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-18.25

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
AXLA
Axcella Health Inc		 - -% - - - - 19.10 0.13
NVO
Novo Nordisk A/S		 -0.37 0.29% 125.79 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.3 2.60% 123.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.06 0.76% 397.70 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 0.06 0.07% 90.16 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Axcella Health Inc

840 Memorial Drive, Cambridge, MA, United States, 02139

Key Executives

Name Title Year Born
Mr. William R. Hinshaw Jr. Pres, CEO & Director 1969
Dr. Alison D. Schecter M.D. Pres of Strategy & Operations 1964
Mr. David R. Epstein B.Sc., M.B.A. Consultant 1962
Mr. Laurent Chardonnet Consultant 1965
Mr. Robert W. Crane Sr. VP & CFO 1959
Dr. Paul Fehlner J.D., Ph.D. Sr. VP, Chief Legal Officer & Corp. Sec. 1964
Ms. Virginia R. Dean Sr. VP & Chief People Officer 1966
Dr. Larry Bell Global Head of Regulatory Affairs & Pharmacovigilance and Sr. VP NA
Dr. Margaret James Koziel M.D. Sr. VP & Chief Medical Officer 1960
Mr. Dan Kirby Sr. VP of Strategic Operations NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).